Kairos Pharma, Ltd. (KAPA)
KAPAAMEXBiotechnology: Pharmaceutical Preparations
$0.4650
-0.0042 (-0.90%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $1.56m
- P/E
- –
- EPS, last 4 quarters
- $-1.96
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.4182 to $7.28
- Average volume
- –
- Previous close
- $0.4692
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $12.00, +2480.6% from here
Earnings
next estimate $-0.6300Next report
Sep 2025
+30.0%
Dec 2025
–
Mar 2026
-14.3%
Jun 2026
+33.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$1.44m | -$1.42m | -$1.69m | -$1.42m |
| Net income | -$1.40m | -$1.36m | -$1.65m | -$1.39m |
News
8 latest- Kairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial RTTNews · Oct 6, 2026
- Kairos Pharma Consensus Price Target Increased by 600.00% to $49.98Fintel · Sep 15, 2026
- Karios Pharma Hits 52-Week Low; Buzz Builds Around Reverse Split And Pipeline Milestone RTTNews · Aug 24, 2026
- All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to BuyZacks · Jul 2, 2026
- Pre-Market Movers: PMI, CNTB, RNAZ Chart The Course RTTNews · Jun 3, 2026
- Kairos Pharma (KAPA) Price Target Decreased by 14.29% to 9.18Fintel · Apr 14, 2026
- Kairos Pharma (KAPA) Price Target Increased by 26.00% to 10.71Fintel · Apr 9, 2026
- Weekly Buzz: MGNX's LINNET Trial On Hold; ETON, ALUR Get FDA Nod; GILD Snaps Up ACLX RTTNews · Feb 27, 2026
The company
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma's lead candidate, ENV-105 (carotuximab), is an antibody targeting CD105 - a protein identified as a key driver of resistance and disease relapse in response to standard cancer therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.